<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: Members of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor family are potent inducers of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in sensitive cells and may be suitable for novel anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies aimed at inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> via the activation of receptors with the <z:hpo ids='HP_0011420'>death</z:hpo> domain on malignant cells </plain></SENT>
<SENT sid="1" pm="."><plain>We characterized the sensitivity of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-related <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-inducing ligand (TRAIL) and anti-Fas <z:chebi fb="4" ids="48705">agonist</z:chebi>, and investigated the mechanism of resistance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines to TRAIL and Fas apoptotic pathways </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Epstein-Barr virus (EBV) status in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines was determined by PCR </plain></SENT>
<SENT sid="3" pm="."><plain>The extent of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> following exposure to TRAIL and anti-Fas <z:chebi fb="4" ids="48705">agonist</z:chebi> was measured by 7A6 antigen staining </plain></SENT>
<SENT sid="4" pm="."><plain>Expression of TRAIL receptors and Fas was determined by flow cytometry and reverse transcriptase-PCR </plain></SENT>
<SENT sid="5" pm="."><plain>Western blot analyses were used to determine the expression of proapoptotic and antiapoptotic proteins </plain></SENT>
<SENT sid="6" pm="."><plain>NF-kappaB activity was evaluated by electrophoretic mobility shift assay </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The sensitivity of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines to anti-Fas <z:chebi fb="4" ids="48705">agonist</z:chebi> depended on the expression of Fas </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, the expression of TRAIL receptors did not correlate with the sensitivity to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Interestingly, EBV-infected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines which showed constitutive levels of NF-kappaB activation, were TRAIL-resistant </plain></SENT>
<SENT sid="10" pm="."><plain>NF-kappaB inhibitors reversed the resistance to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results suggest that activation of NF-kappaB by <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> plays an important role in resistance of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines to TRAIL-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and that NF-kappaB inhibitors may be useful adjuncts in clinical use of TRAIL against <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>